186 related articles for article (PubMed ID: 2163241)
1. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
Kern W; Kennedy SL; Sachdeva M; Sande ER; Gunderson D; Täuber MG
Antimicrob Agents Chemother; 1990 May; 34(5):697-701. PubMed ID: 2163241
[TBL] [Abstract][Full Text] [Related]
2. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
Leleu G; Kitzis MD; Vallois JM; Gutmann L; Decazes JM
Antimicrob Agents Chemother; 1994 Feb; 38(2):195-9. PubMed ID: 8192442
[TBL] [Abstract][Full Text] [Related]
3. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
[TBL] [Abstract][Full Text] [Related]
4. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Islam K; Sime FB; Wallis SC; Bauer MJ; Forde BM; Harris P; Shirin T; Habib ZH; Flora MS; Roberts JA
J Antimicrob Chemother; 2022 Aug; 77(9):2448-2455. PubMed ID: 35724128
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C
Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634
[TBL] [Abstract][Full Text] [Related]
7. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
8. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
[TBL] [Abstract][Full Text] [Related]
9. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
10. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
[No Abstract] [Full Text] [Related]
11. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
Sumi CD; Heffernan AJ; Naicker S; Cottrell K; Wallis SC; Lipman J; Harris PNA; Sime FB; Roberts JA
J Antimicrob Chemother; 2022 Oct; 77(11):3026-3034. PubMed ID: 36031790
[TBL] [Abstract][Full Text] [Related]
12. Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.
Fournier JL; Ramisse F; Jacolot AC; Szatanik M; Petitjean OJ; Alonso JM; Scavizzi MR
Antimicrob Agents Chemother; 1996 Feb; 40(2):325-30. PubMed ID: 8834874
[TBL] [Abstract][Full Text] [Related]
13. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
[TBL] [Abstract][Full Text] [Related]
15. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
16. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
Hou F; Li J; Gao L; Chen Y
Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
Fujita A; Kimura K; Yokoyama S; Jin W; Wachino J; Yamada K; Suematsu H; Yamagishi Y; Mikamo H; Arakawa Y
PLoS One; 2015; 10(11):e0142366. PubMed ID: 26539828
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
VanScoy B; Mendes RE; Nicasio AM; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2013 Jun; 57(6):2809-14. PubMed ID: 23629705
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
Strayer AH; Gilbert DH; Pivarnik P; Medeiros AA; Zinner SH; Dudley MN
Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
